{"id":"cilostazol-group","safety":{"commonSideEffects":[{"rate":"27","effect":"Headache"},{"rate":"19","effect":"Diarrhea"},{"rate":"5","effect":"Palpitations"},{"rate":"9","effect":"Dizziness"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking PDE-3 in platelets and vascular smooth muscle cells, cilostazol elevates intracellular cAMP, which suppresses platelet activation and aggregation while promoting vasodilation. This dual antiplatelet and vasodilatory effect improves blood flow and reduces thrombotic events in peripheral arterial disease.","oneSentence":"Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:34.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermittent claudication due to peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT06757764","phase":"PHASE4","title":"The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-10","conditions":"Cerebral Infarction, Stenosis Artery","enrollment":2340},{"nctId":"NCT07495969","phase":"NA","title":"Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）","status":"NOT_YET_RECRUITING","sponsor":"Feng Gao","startDate":"2026-04-01","conditions":"Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke","enrollment":286},{"nctId":"NCT06504576","phase":"PHASE2","title":"Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-06-16","conditions":"ICH - Intracerebral Hemorrhage","enrollment":100},{"nctId":"NCT07286110","phase":"PHASE1","title":"Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-30","conditions":"Moyamoya Disease, Moyamoya Syndrome","enrollment":66},{"nctId":"NCT07249853","phase":"PHASE3","title":"Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-11-30","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":316},{"nctId":"NCT07238985","phase":"PHASE1, PHASE2","title":"Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Fatty Liver","enrollment":50},{"nctId":"NCT07180472","phase":"PHASE4","title":"Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chengdu Medical College","startDate":"2025-09-20","conditions":"Cerebral Small Vessel Disease","enrollment":632},{"nctId":"NCT06591377","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-10","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT07144956","phase":"PHASE3","title":"Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2025-12-15","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":630},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT05635370","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Peripheral Artery Disease","enrollment":10398},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT07040085","phase":"PHASE3","title":"Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-08-05","conditions":"Stroke","enrollment":892},{"nctId":"NCT06715007","phase":"","title":"Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-20","conditions":"Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity","enrollment":300},{"nctId":"NCT00823849","phase":"PHASE4","title":"Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2008-10","conditions":"Type 2 Diabetes Mellitus, Arteriosclerosis Obliterans","enrollment":200},{"nctId":"NCT06886620","phase":"PHASE3","title":"Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication","status":"TERMINATED","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2016-03-14","conditions":"Intermittent Claudication","enrollment":14},{"nctId":"NCT06117436","phase":"PHASE2, PHASE3","title":"Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-19","conditions":"Wound Heal","enrollment":206},{"nctId":"NCT05759819","phase":"NA","title":"Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Arterial Occlusive Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Medical Devices Co., Ltd. Japan","startDate":"2023-03-10","conditions":"Peripheral Arterial Disease","enrollment":24},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT06612593","phase":"PHASE2","title":"Cilostazol in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-01","conditions":"Parkinson's Disease","enrollment":50},{"nctId":"NCT06591390","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-02-09","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06591299","phase":"PHASE3","title":"Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-04-15","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06591351","phase":"PHASE3","title":"Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06242132","phase":"PHASE3","title":"Clopidogrel Versus Cilostazol in Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-06-01","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06591312","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06242145","phase":"PHASE3","title":"Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2023-01-01","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT06561867","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-30","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06196047","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2023-12-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06202755","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-03-30","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT06530537","phase":"PHASE3","title":"Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-07-18","conditions":"Cerebral Microbleeds, Stroke","enrollment":848},{"nctId":"NCT06138834","phase":"PHASE2","title":"EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-11","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Reperfusion","enrollment":300},{"nctId":"NCT04069819","phase":"NA","title":"The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-08-01","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT01142284","phase":"PHASE2","title":"Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-05-19","conditions":"Peripheral Artery Disease","enrollment":80},{"nctId":"NCT03683628","phase":"NA","title":"Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2018-10-01","conditions":"Intermittent Claudication, PAD, Atherosclerotic Ischemic Disease","enrollment":40},{"nctId":"NCT02554721","phase":"PHASE1","title":"Pharmacodynamic Study of Cilostazol in Healthy Volunteers","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2015-08","conditions":"Healthy","enrollment":77},{"nctId":"NCT01219842","phase":"NA","title":"Invasive Revascularization or Not in Intermittent Claudication","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2010-03","conditions":"Intermittent Claudication","enrollment":159},{"nctId":"NCT02770274","phase":"PHASE3","title":"Cilostazol Following Peripheral Endovascular Procedures","status":"UNKNOWN","sponsor":"Attikon Hospital","startDate":"2016-12","conditions":"Peripheral Arterial Disease","enrollment":200},{"nctId":"NCT04501900","phase":"PHASE4","title":"The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-10","conditions":"Cardiovascular Diseases","enrollment":2106},{"nctId":"NCT04407312","phase":"PHASE4","title":"Cilostazol and Endothelial Progenitor Cell","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2016-01-01","conditions":"Myocardial Infarction, Acute","enrollment":60},{"nctId":"NCT03248401","phase":"PHASE4","title":"Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2016-09-26","conditions":"Type 2 Diabetes Mellitus, Carotid Atherosclerosis","enrollment":50},{"nctId":"NCT03190005","phase":"","title":"Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)","status":"COMPLETED","sponsor":"Taipei City Hospital","startDate":"2017-01-01","conditions":"Stable Angina","enrollment":35},{"nctId":"NCT01261234","phase":"NA","title":"Carotid Artery Stenting With Cilostazol Addition for Restenosis","status":"COMPLETED","sponsor":"Kobe City General Hospital","startDate":"2010-12","conditions":"In-stent Restenosis After Carotid Artery Stenting","enrollment":707},{"nctId":"NCT01291641","phase":"PHASE4","title":"Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-03","conditions":"Hyperlipidemias","enrollment":342},{"nctId":"NCT03318276","phase":"PHASE3","title":"Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2017-02-20","conditions":"Peripheral Arterial Disease","enrollment":170},{"nctId":"NCT01995370","phase":"PHASE4","title":"Cilostazol Stroke Prevention Study for Antiplatelet Combination","status":"COMPLETED","sponsor":"Japan Cardiovascular Research Foundation","startDate":"2013-12-13","conditions":"Noncardioembolic Cerebral Infarction","enrollment":1884},{"nctId":"NCT02829151","phase":"PHASE4","title":"Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-02-21","conditions":"Critical Limb Ischemia","enrollment":390},{"nctId":"NCT00443287","phase":"PHASE2","title":"Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-02","conditions":"Intermittent Claudication","enrollment":553},{"nctId":"NCT01570803","phase":"NA","title":"Efficacy Between Different Two Self-Expanding Nitinol Stents For The Atherosclerotic Femoro-Popliteal Arterial Disease","status":"WITHDRAWN","sponsor":"Korea University Guro Hospital","startDate":"2013-01","conditions":"Arterial Disease, Atherosclerosis","enrollment":""},{"nctId":"NCT02481323","phase":"PHASE2","title":"Lacunar Intervention Trial 1 (LACI-1)","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2016-03","conditions":"Cerebral Small Vessel Diseases, Cognitive Impairment, Stroke","enrollment":57},{"nctId":"NCT01779401","phase":"NA","title":"Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2012-09","conditions":"Coronary Heart Disease","enrollment":1078},{"nctId":"NCT02087007","phase":"PHASE3","title":"A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-11","conditions":"Vasospastic Angina","enrollment":100},{"nctId":"NCT03116269","phase":"PHASE4","title":"The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2012-03-01","conditions":"Ischemic Stroke, Endothelial Dysfunction","enrollment":80},{"nctId":"NCT01192724","phase":"PHASE4","title":"Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03","conditions":"Coronary Artery Disease","enrollment":630},{"nctId":"NCT02933788","phase":"PHASE4","title":"Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients","status":"UNKNOWN","sponsor":"Kangbuk Samsung Hospital","startDate":"2016-10","conditions":"Type 2 Diabetes Mellitus","enrollment":116},{"nctId":"NCT01895400","phase":"PHASE3","title":"Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy","status":"TERMINATED","sponsor":"Jong Woo Chung","startDate":"2013-07","conditions":"Recurrent Vestibulopathy","enrollment":26},{"nctId":"NCT02094469","phase":"PHASE3","title":"Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-12","conditions":"Vasospastic Angina","enrollment":65},{"nctId":"NCT01013532","phase":"PHASE4","title":"PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2009-06","conditions":"Brain Ischemia, Intracranial Hemorrhages","enrollment":1600},{"nctId":"NCT02625714","phase":"PHASE1","title":"Safety/Tolerability and Pharmacokinetic Study of SID142","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-06","conditions":"Arterial Occlusive Diseases","enrollment":41},{"nctId":"NCT01346865","phase":"PHASE4","title":"Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)","status":"TERMINATED","sponsor":"Seung-Jung Park","startDate":"2011-05","conditions":"Coronary Artery Disease","enrollment":402},{"nctId":"NCT01378650","phase":"NA","title":"A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus","status":"COMPLETED","sponsor":"Jong Woo Chung","startDate":"2011-07","conditions":"Tinnitus","enrollment":50},{"nctId":"NCT01409564","phase":"PHASE4","title":"Cilostazol Augmentation Study in Dementia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-05","conditions":"Alzheimer's Dementia","enrollment":46},{"nctId":"NCT01758874","phase":"PHASE2","title":"Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia","status":"COMPLETED","sponsor":"Seoul Veterans Hospital","startDate":"2006-09","conditions":"Critical Limb Ischemia","enrollment":20},{"nctId":"NCT01653600","phase":"PHASE4","title":"Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2012-09","conditions":"Peripheral Arterial Disease, Atherosclerosis","enrollment":346},{"nctId":"NCT01444885","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2011-10","conditions":"Variant Angina","enrollment":50},{"nctId":"NCT01094457","phase":"PHASE4","title":"Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2009-03","conditions":"Acute Coronary Syndromes, Percutaneous Coronary Intervention, Clopidogrel Low Responsiveness","enrollment":840},{"nctId":"NCT01031667","phase":"PHASE4","title":"Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-11","conditions":"Therapy","enrollment":118},{"nctId":"NCT01328470","phase":"PHASE4","title":"Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2009-09","conditions":"Chronic Kidney Disease, Stable Angina","enrollment":85},{"nctId":"NCT00823875","phase":"PHASE4","title":"Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2009-03","conditions":"Atherosclerosis Cerebral Infarction","enrollment":200},{"nctId":"NCT00912756","phase":"PHASE4","title":"Sufficient Treatment of Peripheral Intervention by Cilostazol","status":"UNKNOWN","sponsor":"Kansai Rosai Hospital","startDate":"2009-03","conditions":"Arteriosclerosis Obliterans","enrollment":200},{"nctId":"NCT00915733","phase":"PHASE4","title":"Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism","status":"COMPLETED","sponsor":"Gyeongsang National University Hospital","startDate":"2009-05","conditions":"Myocardial Infarction","enrollment":80},{"nctId":"NCT00938522","phase":"PHASE4","title":"Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-07","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":400},{"nctId":"NCT00891670","phase":"PHASE3","title":"Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2009-05","conditions":"Coronary Artery Stenosis, Maximal Platelet Aggregation, Late Platelet Aggregation","enrollment":80},{"nctId":"NCT00620646","phase":"NA","title":"The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-02","conditions":"Clopidogrel Non-Responsiveness","enrollment":80},{"nctId":"NCT00300339","phase":"PHASE2","title":"Mixed Antagonist of Serotonin for Claudication Optimal Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Intermittent Claudication","enrollment":599},{"nctId":"NCT00573950","phase":"PHASE4","title":"Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2007-12","conditions":"Diabetes Mellitus, Type 2, Metabolic Syndrome X","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":197,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pletaal"],"phase":"marketed","status":"active","brandName":"Cilostazol group","genericName":"Cilostazol group","companyName":"Otsuka Beijing Research Institute","companyId":"otsuka-beijing-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cilostazol is a small molecule inhibitor of the cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A, classified as an INHIBITOR. It has been studied for various conditions, including intermittent claudication, peripheral arterial disease, and cerebral microbleeds, among others, with potential applications in treatments such as percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}